Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

被引：27

作者：

Nooka, Ajay K. ^{[1
]}

Weisel, Katja ^{[2
]}

van de Donk, Niels W. C. J. ^{[3
]}

Routledge, David ^{[4
,5
]}

Otero, Paula Rodriguez ^{[6
]}

Song, Kevin ^{[7
]}

Quach, Hang ^{[8
]}

Callander, Natalie ^{[9
]}

Minnema, Monique C. ^{[10
]}

Trudel, Suzanne ^{[11
]}

Jackson, Nicola A. ^{[12
]}

Ahlers, Christoph M. ^{[13
]}

Im, Ellie ^{[14
]}

Cheng, Shinta ^{[15
]}

Smith, L. ^{[15
]}

Hareth, Nahi ^{[16
]}

Ferron-Brady, Geraldine ^{[13
]}

Brouch, Maria ^{[13
]}

de Oca, Rocio Montes ^{[13
]}

Paul, Sofia ^{[13
]}

Holkova, Beata ^{[13
]}

Gupta, Ira ^{[13
]}

Kremer, Brandon E. ^{[14
]}

Richardson, Paul ^{[17
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA

[2] Univ Med Ctr Hamburg Eppendorf, Dept Oncol Hematol & Bone Marrow Transplantat, D-20246 Hamburg, Germany

[3] Vrije Univ Amsterdam, Amsterdam UMC, Canc Ctr Amsterdam, Dept Hematol, NL-1081 HV Amsterdam, Netherlands

[4] Peter MacCallum Canc Ctr, Melbourne, Vic 3000, Australia

[5] Royal Melbourne Hosp, Melbourne, Vic 3000, Australia

[6] Clin Univ Navarra Pamplona, Ctr Invest Med Aplicada, Navarra 31008, Spain

[7] Vancouver Gen Hosp, Vancouver, BC V5Z 1M9, Canada

[8] Univ Melbourne, St Vincents Hosp Melbourne, Dept Haematol, Melbourne, Vic 3065, Australia

[9] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53705 USA

[10] Univ Med Ctr Utrecht, Dept Hematol, NL-3584 CX Utrecht, Netherlands

[11] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Dept Med, Toronto, ON M5G 2C1, Canada

[12] GlaxoSmithKline, Stockley Pk, London, England

[13] GlaxoSmithKline, Upper Providence, PA 19426 USA

[14] GlaxoSmithKline, Waltham, MA 02451 USA

[15] SpringWorks Therapeut, Stamford, CT 06902 USA

[16] Karolinska Univ Hosp, Dept Med, SE-17176 Stockholm, Sweden

[17] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02215 USA

来源：

FUTURE ONCOLOGY | 2021年 / 17卷 / 16期

关键词：

antibody-drug conjugate; BCMA; belantamab mafodotin; clinical trial; dostarlimab; feladilimab; GSK3174998; multiple myeloma; nirogacestat; platform study;

D O I：

10.2217/fon-2020-1269

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received >= 4 prior therapies. Belamaf binds to BCMA and eliminates myeloma cells by multimodal mechanisms of action. The cytotoxic and potential immunomodulatory properties of belamaf have led to novel combination studies with other anticancer therapies. Here, we describe the rationale and design of DREAMM-5, an ongoing Phase I/II platform study evaluating the safety and efficacy of belamaf combined with novel agents, including GSK3174998 (OX40 agonist), feladilimab (an ICOS; GSK3359609), nirogacestat (a gamma-secretase inhibitor; PF-03084014) and dostarlimab (a PD-1 blocker) versus belamaf monotherapy for patients with relapsed/refractory multiple myeloma.

引用

页码：1987 / 2003

页数：17

共 87 条

[1] Adaptive platform trials: definition, design, conduct and reporting considerations The Adaptive Platform Trials Coalition
Angus, Derek C.
Alexander, Brian M.
Berry, Scott
Buxton, Meredith
Lewis, Roger
Paoloni, Melissa
Webb, Steven A. R.
Arnold, Steven
Barker, Anna
Berry, Donald A.
Bonten, Marc J. M.
Brophy, Mary
Butler, Christopher
Cloughesy, Timothy F.
Derde, Lennie P. G.
Esserman, Laura J.
Ferguson, Ryan
Fiore, Louis
Gaffey, Sarah C.
Gaziano, J. Michael
Giusti, Kathy
Goossens, Herman
Heritier, Stephane
Hyman, Bradley
Krams, Michael
Larholt, Kay
LaVange, Lisa M.
Lavori, Philip
Lo, Andrew W.
London, Alex John
Manax, Victoria
McArthur, Colin
O'Neill, Genevieve
Parmigiani, Giovanni
Perlmutter, Jane
Petzold, Elizabeth A.
Ritchie, Craig
Rowan, Kathryn M.
Seymour, Christopher W.
Shapiro, Nathan, I
Simeone, Diane M.
Smith, Bradley
Spellberg, Bradley
Stern, Ariel Dora
Trippa, Lorenzo
Trusheim, Mark
Viele, Kert
Wen, Patrick Y.
Woodcock, Janet
[J]. NATURE REVIEWS DRUG DISCOVERY, 2019, 18 (10) : 797 - 807
[2] Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Ahmadzadeh, Mojgan
Johnson, Laura A.
Heemskerk, Bianca
Wunderlich, John R.
Dudley, Mark E.
White, Donald E.
Rosenberg, Steven A.
[J]. BLOOD, 2009, 114 (08) : 1537 - 1544
[3] [Anonymous], 2020, STUDY BELANTAMAB MAF
[4] Potent activity of soluble B7RP-1-FC in therapy of murine tumors in syngeneic hosts
Ara, G
Baher, A
Storm, N
Horan, T
Baikalov, C
Brisan, E
Camacho, R
Moore, A
Goldman, H
Kohno, T
Cattley, RC
Van, G
Gaida, K
Zhang, M
Whoriskey, JS
Fong, D
Yoshinaga, SK
[J]. INTERNATIONAL JOURNAL OF CANCER, 2003, 103 (04) : 501 - 507
[5] Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
Atanackovic, D.
Luetkens, T.
Kroeger, N.
[J]. LEUKEMIA, 2014, 28 (05) : 993 - 1000
[6] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
Badros, Ashraf
Hyjek, Elizabeth
Ma, Ning
Lesokhin, Alexander
Dogan, Ahmet
Rapoport, Aaron P.
Kocoglu, Mehmet
Lederer, Emily
Philip, Sunita
Milliron, Todd
Dell, Cameron
Goloubeva, Olga
Singh, Zeba
[J]. BLOOD, 2017, 130 (10) : 1189 - 1197
[7] The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Benson, Don M., Jr.
Bakan, Courtney E.
Mishra, Anjali
Hofmeister, Craig C.
Efebera, Yvonne
Becknell, Brian
Baiocchi, Robert A.
Zhang, Jianying
Yu, Jianhua
Smith, Megan K.
Greenfield, Carli N.
Porcu, Pierluigi
Devine, Steven M.
Rotem-Yehudar, Rinat
Lozanski, Gerard
Byrd, John C.
Caligiuri, Michael A.
[J]. BLOOD, 2010, 116 (13) : 2286 - 2294
[8] Brett S, 2018, ANN ONCOL, V29
[9] Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice
Chen, Yu
Pei, Yanqing
Luo, Jingyu
Huang, Zhaoqin
Yu, Jinming
Meng, Xiangjiao
[J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
[10] BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma
Cho, Shih-Feng
Lin, Liang
Xing, Lijie
Li, Yuyin
Yu, Tengteng
Anderson, Kenneth C.
Tai, Yu-Tzu
[J]. CANCERS, 2020, 12 (06) : 1 - 29

← 1 2 3 4 5 6 7 8 9 →